12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MM-121: Phase II data

Top-line data from a cohort of NSCLC patients whose disease progressed after EGFR therapy (n=50) in a single-arm, open-label, international Phase II trial showed that MM-121 plus Tarceva erlotinib missed the primary endpoint of a 4-month PFS rate of >=40%. Merrimack declined to disclose details. The trial is also evaluating MM-121 plus Tarceva in 2 other patient cohorts - NSCLC patients...

Read the full 301 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >